000157345 001__ 157345
000157345 005__ 20240229133507.0
000157345 0247_ $$2doi$$a10.1038/s41375-020-0976-9
000157345 0247_ $$2pmid$$apmid:32684633
000157345 0247_ $$2ISSN$$a0887-6924
000157345 0247_ $$2ISSN$$a1476-5551
000157345 0247_ $$2altmetric$$aaltmetric:86113081
000157345 037__ $$aDKFZ-2020-01574
000157345 041__ $$aeng
000157345 082__ $$a610
000157345 1001_ $$00000-0002-6226-1252$$aMai, Elias K$$b0
000157345 245__ $$aBortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
000157345 260__ $$aLondon$$bSpringer Nature$$c2021
000157345 3367_ $$2DRIVER$$aarticle
000157345 3367_ $$2DataCite$$aOutput Types/Journal article
000157345 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1614946019_14401
000157345 3367_ $$2BibTeX$$aARTICLE
000157345 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157345 3367_ $$00$$2EndNote$$aJournal Article
000157345 500__ $$a2021 Mar;35(3):809-822
000157345 520__ $$aIntensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell transplantation (ASCT) followed by consolidation and/or maintenance is mostly restricted to patients up to 65 years of age. Prospective phase III trial data in the era of novel agents for patients up to 70 years of age are not available. The GMMG-MM5 trial included 601 patients between 18 and 70 years of age, divided in three groups for the present analysis: ≤60 years (S1, n = 353), 61-65 years (S2, n = 107) and 66-70 years (S3, n = 141). Treatment consisted of a bortezomib-containing IT, MEL200/ASCT, consolidation, and maintenance with lenalidomide. Adherence to treatment was similar among patients of the three age groups. Overall toxicity during all treatment phases was increased in S2 and S3 compared to S1 (any adverse event/any serious adverse event: S1:81.7/41.8% vs. S2:90.7/56.5% vs. S3:87.2/68.1%, p = 0.05/<0.001). With respect to progression-free survival (log-rank p = 0.73), overall survival (log-rank p = 0.54) as well as time-to-progression (Gray's p = 0.83) and non-relapse mortality (Gray's p = 0.25), no differences were found between the three age groups. Our results imply that an intensive upfront therapy with a bortezomib-containing IT, MEL200/ASCT, lenalidomide consolidation, and maintenance should be applied to transplant-eligible MM patients up to 70 years of age.
000157345 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000157345 588__ $$aDataset connected to CrossRef, PubMed,
000157345 7001_ $$0P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aMiah, Kaya$$b1$$udkfz
000157345 7001_ $$aBertsch, Uta$$b2
000157345 7001_ $$aDürig, Jan$$b3
000157345 7001_ $$aScheid, Christof$$b4
000157345 7001_ $$aWeisel, Katja C$$b5
000157345 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b6
000157345 7001_ $$aMunder, Markus$$b7
000157345 7001_ $$aLindemann, Hans-Walter$$b8
000157345 7001_ $$aMerz, Maximilian$$b9
000157345 7001_ $$aHose, Dirk$$b10
000157345 7001_ $$aJauch, Anna$$b11
000157345 7001_ $$aSeckinger, Anja$$b12
000157345 7001_ $$aLuntz, Steffen$$b13
000157345 7001_ $$aSauer, Sandra$$b14
000157345 7001_ $$aFuhrmann, Stephan$$b15
000157345 7001_ $$aBrossart, Peter$$b16
000157345 7001_ $$aElmaagacli, Ahmet$$b17
000157345 7001_ $$aGoerner, Martin$$b18
000157345 7001_ $$aBernhard, Helga$$b19
000157345 7001_ $$aHoffmann, Martin$$b20
000157345 7001_ $$aRaab, Marc S$$b21
000157345 7001_ $$aBlau, Igor W$$b22
000157345 7001_ $$aHänel, Mathias$$b23
000157345 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b24$$udkfz
000157345 7001_ $$aSalwender, Hans J$$b25
000157345 7001_ $$aGoldschmidt, Hartmut$$b26
000157345 7001_ $$aGroup, German-speaking Myeloma Multicenter$$b27$$eCollaboration Author
000157345 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/s41375-020-0976-9$$n3$$p809-822$$tLeukemia$$v35$$x1476-5551$$y2021
000157345 909CO $$ooai:inrepo02.dkfz.de:157345$$pVDB
000157345 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b97fc5666ea8f9db9ef499de6b2397cf$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000157345 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000157345 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000157345 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157345 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000157345 9141_ $$y2021
000157345 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2018$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-10
000157345 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bLEUKEMIA : 2018$$d2020-01-10
000157345 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000157345 980__ $$ajournal
000157345 980__ $$aVDB
000157345 980__ $$aI:(DE-He78)C060-20160331
000157345 980__ $$aUNRESTRICTED